First Parkinson’s drug to treat hallucinations and delusions is approved

News

Author: AdminPublished: 6 May 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A new antipsychotic drug to treat symptoms of psychosis associated with Parkinson’s disease like hallucinations and delusions has become the first to be approved by the FDA.

The drug, called Nuplazid (pimavanserin), is the first of its kind on the market for use by people living with Parkinson’s in the US. It works only on the serotonin system, meaning – unlike previous antipsychotic medication – it doesn’t worsen motor symptoms.

It is estimated that around half the people with the condition may at some point experience hallucinations (seeing things that aren’t there) or delusions (holding false, paranoid, beliefs), also referred to as psychosis.

Dr Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said: “Nuplazid represents an important treatment for people with Parkinson’s.”

Nuplazid is developed by Acadia Pharmaceuticals and will be available from June 2016 at the estimated annual cost of US$23,400.

Go Back

Share this story

Comments


Related articles


MRI scan

sponsored article

Advances

EU approval for Medtronic DBS systems improves access to full-body MRI scans

Patients receiving DBS therapy have the option of full-body MRI scans

READ MORE
Parkinson's

Europe

“The beginning of a wonderful collaboration between countries, organisations and people”

The EPDA hosted a two-day event last week

READ MORE

Special reports

How virtual reality is giving Parkinson’s patients a ‘disease-free’ Second Life

Second Life: a (virtual) world without Parkinson’s

READ MORE